Literature DB >> 11576850

The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.

M Philpott1, L M Ching, B C Baguley.   

Abstract

5,6-dimethylxanthenone-4-acetic acid (DMXAA), currently in phase I trials, demonstrates excellent activity against transplantable murine tumours with established vasculature. The induction of cytokines, particularly of tumour necrosis factor (TNF), appears to be critical to its action. We investigated TNF induction by DMXAA in cultured human peripheral blood leucocytes (HPBL). TNF was measured by an enzyme-linked immunosorbent assay after 8 h, and NF-kappaB induction by electrophoretic mobility shift assays (EMSA) after 2 h. DMXAA (800 microg/ml) had no effect alone on TNF production but augmented, by up to 4-fold, the ability of bacterial lipopolysaccharide (LPS) to induce TNF. Previously reported results showing TNF production by DMXAA alone were traced to the presence in an earlier batch of DMXAA of a small amount of LPS, the action of which could be blocked by polymyxin B. DMXAA stimulated TNF production by deacylated LPS, which alone had little effect. An antibody (MEM-18) to the CD14 receptor, while blocking the induction of TNF by LPS, enabled DMXAA to both synthesise TNF and induce NF-kappaB. The structurally related drug, flavone acetic acid (FAA), did not induce TNF or synergise with anti-CD14 antibody. DMXAA strongly augmented the ability of suboptimal concentrations of interleukin-1 (IL-1) (25 ng/ml), okadaic acid (OA) (20 ng/ml) and phorbol-12-myristate-13-acetate (PMA) (5 ng/ml) to induce TNF production, suggesting that it affects multiple pathways converging on NF-kappaB activation. Sodium salicylate, a drug reported to inhibit the beta-subunit of IkappaB kinase (IKK), appeared to competitively inhibit TNF production by DMXAA in the presence of anti-CD14 antibody. Taken together, the results indicate DMXAA acts in vitro on HPBL to co-stimulate TNF production by a wide variety of agents, and suggests that IKK is the target that mediates this action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576850     DOI: 10.1016/s0959-8049(01)00210-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

Review 1.  Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Authors:  Bruce C Baguley; Dietmar W Siemann
Journal:  Expert Opin Investig Drugs       Date:  2010-11       Impact factor: 6.206

2.  Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.

Authors:  Romy Brauer; Liang-Chuan S Wang; See-Tarn Woon; David J A Bridewell; Kimiora Henare; Dieter Malinger; Brian D Palmer; Stefanie N Vogel; Claudine Kieda; Sofian M Tijono; Lai-Ming Ching
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

3.  Species-specific detection of the antiviral small-molecule compound CMA by STING.

Authors:  Taner Cavlar; Tobias Deimling; Andrea Ablasser; Karl-Peter Hopfner; Veit Hornung
Journal:  EMBO J       Date:  2013-04-19       Impact factor: 11.598

4.  The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.

Authors:  Zachary J Roberts; Nadege Goutagny; Pin-Yu Perera; Hiroki Kato; Himanshu Kumar; Taro Kawai; Shizuo Akira; Ram Savan; David van Echo; Katherine A Fitzgerald; Howard A Young; Lai-Ming Ching; Stefanie N Vogel
Journal:  J Exp Med       Date:  2007-06-11       Impact factor: 14.307

5.  Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.

Authors:  L-M Ching; Z Cao; C Kieda; S Zwain; M B Jameson; B C Baguley
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.